ANSWER: A

Rationale:

This case opening requires selecting the optimal agent for an antipsychotic switch in a patient with established metabolic syndrome, integrating the indication, metabolic evidence, and mechanistic pharmacology. Lurasidone satisfies all three criteria for this clinical decision. First, indication: lurasidone is FDA-approved for schizophrenia and is therefore an appropriate replacement for olanzapine. Second, metabolic evidence: clinical trial data for lurasidone demonstrates average weight gain of approximately 0.7 kg at 6 weeks, minimal effects on fasting glucose, and minimal effects on lipid parameters — the combination of which directly addresses this patient's three established metabolic syndrome components. Third, mechanistic pharmacology: lurasidone's favorable metabolic profile is explained by its low affinity for H1 histamine receptors and low affinity for 5-HT2C serotonin receptors. H1 antagonism drives weight gain through central appetite stimulation, and 5-HT2C antagonism also promotes orexigenic signaling; olanzapine has high affinity for both, which accounts for its substantial metabolic liability. Lurasidone's low affinity at these receptors removes both primary drivers of antipsychotic-induced weight gain and metabolic dysregulation.

• Option B: Option B is incorrect because aripiprazole's D2 partial agonism does not produce a class-specific metabolic advantage through peripheral receptor effects in adipose tissue; aripiprazole does have a relatively favorable metabolic profile, but the mechanism is receptor-profile-based (low H1, low 5-HT2C) not a consequence of partial versus full agonism, and aripiprazole lacks a specific bipolar depression-focused rationale to displace lurasidone here; more importantly, lurasidone has the most directly applicable clinical evidence for the specific metabolic parameters affected in this patient.
• Option C: Option C is incorrect because ziprasidone's favorable metabolic profile is not explained by aldehyde oxidase-mediated metabolism avoiding lipogenic CYP metabolites; this mechanism is pharmacokinetically implausible and unsupported by evidence — ziprasidone's metabolic profile reflects its receptor binding characteristics (low H1, low 5-HT2C), not its metabolic pathway.
• Option D: Option D is incorrect because asenapine's sublingual route does not produce lower systemic drug concentrations than a dose-equivalent oral antipsychotic; sublingual asenapine achieves approximately 35% bioavailability and full therapeutic systemic exposure; the metabolic effects occur from these systemic concentrations regardless of the route.

ANSWER: B

Rationale:

The essential lurasidone administration instruction is food co-administration with a minimum of 350 calories per dose. Lurasidone's oral bioavailability increases approximately three-fold when taken with an adequate meal compared with fasting; taking it with only water or negligible caloric intake is pharmacokinetically equivalent to fasting administration and produces plasma levels approximately one-third of the fed-state value at the same dose. For this patient who is being switched to lurasidone partly because of metabolic concerns, understanding that the medication's effectiveness depends on consistent food co-administration is critical — skipping meals or eating very small amounts at dosing time will produce apparent treatment failure that could be misidentified as inadequate antipsychotic dosing or non-adherence. Patient counseling should specify the minimum 350-calorie threshold and explain that the type of food matters less than the total caloric content. The medication can be taken at any time of day as long as adequate food is consumed simultaneously.

• Option A: Option A is incorrect because lurasidone does not produce clinically significant orthostatic hypotension requiring supine positioning during absorption; there is no pharmacokinetic or pharmacodynamic requirement for bedtime administration specific to lurasidone, and the food requirement is the clinically essential instruction, not postural precautions.
• Option C: Option C is incorrect because lurasidone's half-life is approximately 18 hours — not 7 hours — making once-daily dosing pharmacokinetically appropriate; the 7-hour half-life describes ziprasidone, not lurasidone, and once-daily dosing with lurasidone does not require a strict 2-hour deviation window for consistent therapeutic coverage.
• Option D: Option D is incorrect because lurasidone does not cause esophageal injury or require upright positioning; this instruction is associated with bisphosphonate medications and is not relevant to lurasidone; the critical instruction is food co-administration for bioavailability, not postural requirements for tablet safety.

ANSWER: C

Rationale:

This question applies the lurasidone CYP3A4 contraindication to one of its most clinically common real-world contexts: HIV antiretroviral therapy. Ritonavir is among the most potent CYP3A4 inhibitors in clinical use and is widely employed as a pharmacokinetic booster in HIV regimens precisely because of its ability to dramatically increase plasma levels of co-administered CYP3A4 substrates. Lurasidone depends exclusively on CYP3A4 for its metabolism — it has no alternative pathway to maintain clearance when CYP3A4 is inhibited. Ritonavir's CYP3A4 inhibition reduces lurasidone clearance to near zero through its only metabolic route, producing plasma level increases that are too large and unpredictable to manage with dose adjustment. The FDA prescribing information for lurasidone designates co-administration with strong CYP3A4 inhibitors as contraindicated. The correct clinical approach is to communicate the contraindication to the infectious disease physician and work collaboratively to identify an antiretroviral regimen that does not include ritonavir or other strong CYP3A4 inhibitors (for example, integrase strand transfer inhibitor-based regimens that have minimal CYP3A4 involvement), or to transition the patient to an antipsychotic whose metabolic pathway accommodates CYP3A4 inhibition.

• Option A: Option A is incorrect because applying the 50% dose reduction rule for a single-pathway inhibitor to lurasidone fundamentally misapplies the management framework; this 50% rule is appropriate for aripiprazole because it retains a secondary CYP2D6 pathway — lurasidone has no alternative pathway and the prescribing information classifies the combination as contraindicated, not manageable by dose reduction.
• Option B: Option B is incorrect because the 75% reduction rule applies to simultaneous inhibition of both CYP2D6 and CYP3A4 for dual-pathway drugs; applying it to lurasidone is based on the false premise that a larger dose reduction can address exclusive single-pathway dependency, which the prescribing information does not support.
• Option D: Option D is incorrect because protein binding does not protect a drug from CYP3A4-mediated metabolism; free drug and protein-bound drug exist in rapid equilibrium, and as free drug is cleared by CYP3A4, bound drug dissociates to replenish the free fraction; when CYP3A4 clearance is inhibited, the equilibrium shifts to elevate total (free plus bound) drug concentrations; high protein binding does not limit the pharmacokinetic interaction.

ANSWER: D

Rationale:

This question completes the bidirectional CYP3A4 contraindication principle for lurasidone: exclusive CYP3A4 dependence creates absolute contraindications in both directions — strong inhibitors raise levels to potentially toxic, unmanageable concentrations, and strong inducers reduce levels to potentially subtherapeutic, unmanageable concentrations. Efavirenz is classified as a strong CYP3A4 inducer, capable of substantially increasing CYP3A4 enzymatic activity and accelerating the metabolism of CYP3A4-dependent substrates. For lurasidone, which has no alternative metabolic pathway to compensate when CYP3A4-mediated clearance is dramatically accelerated, efavirenz induction can reduce lurasidone plasma levels to concentrations that are insufficient for antipsychotic effect regardless of dose increases — the magnitude of CYP3A4 induction at standard efavirenz doses is too large to reliably correct through dose escalation. The FDA prescribing information for lurasidone classifies co-administration with strong CYP3A4 inducers as contraindicated, parallel to its contraindication with strong CYP3A4 inhibitors. The clinical management is to discuss with the HIV treatment team the feasibility of an induction-free antiretroviral regimen, or to transition the patient to an antipsychotic with a metabolic pathway unaffected by CYP3A4 induction — for example, an agent metabolized primarily by CYP2D6, glucuronidation, or aldehyde oxidase. This case illustrates that exclusive single-enzyme metabolic dependence creates a pharmacokinetic vulnerability in both directions along the induction-inhibition spectrum, not just in the direction of inhibition.

• Option A: Option A is incorrect because dose-doubling applies to aripiprazole with CYP3A4 inducers specifically because aripiprazole retains a secondary CYP2D6 pathway; the doubling compensates for the induction-accelerated CYP3A4 clearance because CYP2D6 continues to provide baseline clearance; lurasidone has no such secondary pathway and its prescribing information designates the combination as contraindicated rather than recommending dose adjustment.
• Option B: Option B is incorrect because efavirenz is classified as a strong CYP3A4 inducer at standard doses, and characterizing it as moderate understates the interaction risk; regardless of degree, the prescribing information contraindication for lurasidone with strong CYP3A4 inducers applies to efavirenz.
• Option C: Option C is incorrect because lurasidone does not have a sufficiently wide therapeutic window to tolerate the substantial plasma level reductions produced by strong CYP3A4 inducers; the prescribing information contraindication exists precisely because the level reduction is clinically significant and not adequately managed by monitoring and reactive dose escalation.

ANSWER: B

Rationale:

Aripiprazole is metabolized by both CYP2D6 and CYP3A4. Carbamazepine is one of the most potent CYP3A4 inducers in clinical use, substantially increasing CYP3A4 enzymatic activity and accelerating aripiprazole's metabolism through this pathway. The net result is a reduction in aripiprazole plasma levels of approximately 50%, which can produce subtherapeutic antipsychotic exposure if the dose is not adjusted. The FDA prescribing information for aripiprazole specifically recommends doubling the aripiprazole dose when carbamazepine or another strong CYP3A4 inducer is added: 15 mg × 2 = 30 mg daily. This dose-doubling compensates for the increased CYP3A4-mediated clearance while aripiprazole's CYP2D6 pathway continues to provide its usual contribution to overall clearance. The patient and clinical team should be aware that if carbamazepine is subsequently discontinued, aripiprazole levels will rise as the CYP3A4 induction resolves, and the dose must be reduced back to 15 mg over 1 to 2 weeks to avoid toxicity.

• Option A: Option A is incorrect because carbamazepine is a CYP3A4 inducer, not a CYP2D6 inhibitor; it does not produce an offsetting CYP2D6 inhibitory effect that would reduce aripiprazole clearance; the pharmacokinetic consequence of carbamazepine addition is accelerated aripiprazole clearance requiring a dose increase, not a decrease.
• Option C: Option C is incorrect because while CYP2D6 is an important aripiprazole pathway, CYP3A4 contributes sufficiently to overall clearance that strong induction of CYP3A4 alone produces a clinically significant reduction in aripiprazole levels requiring dose adjustment; the prescribing information explicitly addresses this interaction with a specific dose-doubling recommendation.
• Option D: Option D is incorrect because carbamazepine's sodium channel blocking mechanism does not produce pharmacodynamic interactions at D2 receptors that interfere with CYP3A4-dependent antipsychotics; the interaction is purely pharmacokinetic, and the correct management is dose adjustment rather than drug substitution.

ANSWER: C

Rationale:

This question applies understanding of CYP3A4 induction pharmacokinetics to the clinical management of induction reversal. CYP3A4 induction by carbamazepine is a transcriptional process: carbamazepine activates nuclear receptors that drive increased synthesis of CYP3A4 protein, raising the total amount of active enzyme in the liver. This induction develops over days to weeks as new enzyme is synthesized. When carbamazepine is discontinued, the transcriptional induction stimulus is removed and CYP3A4 enzyme levels return to the uninduced baseline — but this reversal also takes time, approximately 1 to 2 weeks, as the excess enzyme protein is degraded through normal protein turnover and is not replaced at the previously elevated rate. During this 1-to-2-week reversal period, CYP3A4-mediated clearance of aripiprazole progressively decreases toward baseline, and aripiprazole plasma levels rise from the sub-therapeutic levels induced by carbamazepine. If the aripiprazole dose is not reduced proportionally during this period, the patient will experience rising plasma levels that can produce dose-dependent adverse effects — sedation, extrapyramidal symptoms, and other toxicity — as the induction resolves. The appropriate management is to begin reducing aripiprazole toward the original 15 mg dose over approximately 1 to 2 weeks following carbamazepine discontinuation, with monitoring for emerging adverse effects.

• Option A: Option A is incorrect because CYP3A4 induction does not cease immediately when carbamazepine is stopped; the already-synthesized CYP3A4 enzyme continues to be present and metabolically active until it is degraded through normal protein turnover over 1 to 2 weeks; immediate dose reduction to 15 mg on the day of carbamazepine discontinuation would be premature and would not match the gradual reversal of induction.
• Option B: Option B is incorrect because CYP3A4 induction is not permanent; it is a reversible transcriptional response that resolves over approximately 1 to 2 weeks after the inducer is withdrawn as enzyme levels return to baseline; maintaining aripiprazole at 30 mg after induction resolves would leave the patient on double the necessary dose once CYP3A4 activity normalizes.
• Option D: Option D is incorrect because there is no established rebound inhibitory phase following cessation of CYP3A4 inducers; CYP3A4 activity returns smoothly to its uninduced baseline after inducer withdrawal without overshooting below pre-induction levels; this mechanism would represent a pharmacological phenomenon not supported by established CYP induction physiology.

ANSWER: D

Rationale:

This question requires integrating pharmacogenomics with the CYP3A4 induction interaction, recognizing that the two factors operate in different clinical domains. The CYP2D6 poor metabolizer status affects aripiprazole's baseline pharmacokinetics: because aripiprazole is metabolized by both CYP2D6 and CYP3A4, a CYP2D6 poor metabolizer has higher aripiprazole plasma levels than an extensive metabolizer at the same dose, due to absent CYP2D6-mediated clearance. This genotype-level effect is relevant to establishing the appropriate baseline aripiprazole dose before any drug interactions are introduced — this patient may have required a lower-than-standard starting dose (for example, 10 mg instead of 15 mg) to achieve the same therapeutic exposure. However, the CYP3A4 induction interaction with carbamazepine is superimposed on top of whatever baseline was established for this patient. The dose-doubling principle for carbamazepine applies to aripiprazole's CYP3A4 pathway: carbamazepine substantially increases CYP3A4 activity, and the appropriate compensatory response is to double the current dose — whatever that dose is — to maintain approximately the same exposure as at the pre-induction baseline. If the baseline dose was 15 mg (as in this case, perhaps suboptimal for a poor metabolizer but tolerated), the carbamazepine-corrected dose is 30 mg. The two pharmacogenomic and pharmacokinetic adjustments are conceptually independent: CYP2D6 status governs baseline dosing; the carbamazepine interaction governs the induction-period dose adjustment; and the latter applies to the former.

• Option A: Option A is incorrect because it conflates the effect of absent CYP2D6 on baseline clearance with the effect of CYP3A4 induction; losing CYP2D6 does not cancel the need for dose doubling when CYP3A4 is induced; CYP3A4 induction by carbamazepine reduces aripiprazole levels regardless of CYP2D6 status, and dose doubling remains appropriate.
• Option B: Option B is incorrect because the dose-doubling principle is based on the percentage reduction in aripiprazole AUC produced by CYP3A4 induction (approximately 50%), not on the absolute clearance baseline; the proportional interaction magnitude is similar in poor and extensive metabolizers, so tripling is not supported by the pharmacokinetic data or the prescribing information.
• Option C: Option C is incorrect because while the carbamazepine dose-doubling principle itself applies to both metabolizer types, the answer oversimplifies by ignoring that CYP2D6 poor metabolizer status is relevant to the baseline dose from which the doubling proceeds — the complete answer acknowledges both dimensions.

ANSWER: A

Rationale:

This question integrates CYP2D6 pharmacogenomics directly with the dual-pathway inhibition dose reduction framework for aripiprazole. As established in the earlier case questions, this patient genetically lacks functional CYP2D6 activity. From aripiprazole's pharmacokinetic perspective, absent CYP2D6 function is equivalent to having CYP2D6 maximally and permanently inhibited — in both cases, CYP2D6-mediated clearance of aripiprazole is zero. When itraconazole is then added and strongly inhibits CYP3A4, aripiprazole's second primary clearance pathway is also non-functional. The patient is now in the pharmacokinetic equivalent of dual-pathway inhibition: absent CYP2D6 (genetic) plus inhibited CYP3A4 (pharmacological) = both primary metabolic pathways blocked. The prescribing guidance for aripiprazole with dual-pathway inhibition recommends reducing the dose to approximately 25% of the current dose: 15 mg × 25% = 3.75 mg for the duration of itraconazole co-administration. When itraconazole is discontinued, the aripiprazole dose should be restored to the level appropriate for a CYP2D6 poor metabolizer with uninhibited CYP3A4 — which is 15 mg in this case, noting that a lower dose may in principle be more appropriate for this genotype depending on tolerability.

• Option B: Option B is incorrect because applying the standard 50% single-pathway CYP3A4 inhibition rule fails to account for the patient's absent CYP2D6; in an extensive metabolizer, CYP2D6 would continue to provide partial clearance when CYP3A4 is inhibited, limiting the level increase to approximately two-fold; in this poor metabolizer, CYP2D6 provides zero clearance, so inhibiting CYP3A4 removes the only functional pathway — producing a much larger level increase than a simple 50% reduction would address.
• Option C: Option C is incorrect because the clinical significance of adding itraconazole to a CYP2D6 poor metabolizer on aripiprazole is not zero; while it is true that this patient was already relying more heavily on CYP3A4, that pathway was functional at baseline; itraconazole's inhibition of CYP3A4 now eliminates the only remaining active clearance route, substantially raising aripiprazole levels from their already-elevated poor-metabolizer baseline.
• Option D: Option D is incorrect because unlike lurasidone, which has no alternative metabolic pathway at all, aripiprazole in this situation has residual minor metabolic contributions beyond CYP2D6 and CYP3A4, and the interaction is manageable with dose reduction to 25%; aripiprazole is not absolutely contraindicated in this scenario but does require the 25% dose adjustment.

ANSWER: C

Rationale:

The attending's caution is based directly on cariprazine's DDCAR pharmacokinetics. Cariprazine's major active metabolite, DDCAR, has an elimination half-life of several weeks — substantially longer than the parent drug's 2-to-4-day half-life. After the dose was increased from 1.5 mg to 3 mg at week 2, the parent drug reached its new steady state within approximately 10 to 14 days. However, DDCAR continues to accumulate toward its new steady-state concentration for 4 to 8 weeks after the dose change. At week 3 — only one week after the dose increase to 3 mg — DDCAR is still well below its final steady-state concentration at this dose. The antipsychotic effect of the 3 mg dose, which depends substantially on DDCAR's D2 and D3 receptor occupancy contribution, is therefore only partially expressed at week 3. If the team escalates to 6 mg based on the week 3 assessment, they will be adding additional drug to a system where DDCAR from the 3 mg dose is still accumulating; over the following weeks, DDCAR from the 6 mg dose accumulates on top of still-accumulating DDCAR from the previous level, potentially producing a total active drug exposure substantially higher than intended — with risk of emerging adverse effects as DDCAR reaches steady state at the higher dose. The appropriate response is to reassess at week 6 to week 8, when DDCAR has reached steady state at the 3 mg dose and a reliable clinical response evaluation can be performed.

• Option A: Option A is incorrect because while clinical guideline observation periods exist, the attending's specific reasoning in this case is pharmacokinetic — DDCAR accumulation kinetics provide a precise, mechanistically grounded reason to avoid dose escalation at week 3 that goes beyond a general guideline recommendation.
• Option B: Option B is incorrect because cariprazine does not undergo CYP3A4 auto-induction; auto-induction is not an established pharmacological property of cariprazine, and the premise of falling plasma levels over 6 to 8 weeks due to self-induction is pharmacokinetically inaccurate.
• Option D: Option D is incorrect because D2 receptor downregulation from cariprazine's partial agonism does not produce a 4-to-6-week stabilization period that makes early dose escalation dangerous through paradoxical dopaminergic stimulation; the mechanism of caution is DDCAR pharmacokinetics, not receptor tolerance development.

ANSWER: D

Rationale:

This question integrates two pharmacokinetic principles: the cariprazine CYP3A4 inhibitor management rule (halve the dose) and the DDCAR half-life consequence for the duration of monitoring required. Telithromycin is a potent CYP3A4 inhibitor. When co-administered with cariprazine, it substantially reduces cariprazine's CYP3A4-mediated clearance, raising both cariprazine and DDCAR plasma levels. The prescribing information recommends halving the cariprazine dose when a strong CYP3A4 inhibitor is added: 3 mg → 1.5 mg daily. This is a dose reduction, not a contraindication — cariprazine retains minor alternative pathways that distinguish it from lurasidone's exclusive CYP3A4 dependence. The clinically important additional point specific to cariprazine is DDCAR's multi-week half-life: even though telithromycin's prescribed course is only 5 days, the pharmacokinetic consequence of the CYP3A4 inhibition on DDCAR accumulation does not resolve in 5 days. DDCAR's slow accumulation means that the elevated total active drug exposure from the inhibition period continues to manifest for weeks after the interaction begins — the level change is not a rapid on-off phenomenon but a slow pharmacokinetic shift. Ongoing monitoring for emerging adverse effects is therefore warranted well beyond the 5-day antibiotic course, and the cariprazine dose should remain reduced until DDCAR levels have stabilized at the lower level.

• Option A: Option A is incorrect because a 5-day strong CYP3A4 inhibition period does produce a clinically meaningful pharmacokinetic interaction with cariprazine through its effect on DDCAR accumulation; because DDCAR's half-life is measured in weeks, even a brief inhibition period can initiate a DDCAR accumulation trajectory that continues for weeks, making the interaction clinically significant despite the short antibiotic course.
• Option B: Option B is incorrect because the combination of cariprazine and a strong CYP3A4 inhibitor is not absolutely contraindicated — unlike lurasidone's exclusive CYP3A4 dependence, cariprazine retains minor alternative metabolic pathways and the interaction is managed with dose reduction; discontinuation is not required.
• Option C: Option C is correct but incomplete: while it correctly identifies the dose reduction and acknowledges the DDCAR persistence issue, it does not specify that monitoring is required well after the antibiotic course ends as clearly as Option D, making D the more complete and actionable answer for clinical guidance.

ANSWER: A

Rationale:

This question requires applying knowledge of telithromycin's pharmacokinetic inhibition properties rather than relying solely on cariprazine's DDCAR kinetics. While DDCAR's long half-life is relevant (Option D), the more immediate and specific reason for the timing concern is that telithromycin's CYP3A4 inhibitory effect does not end on the day the last tablet is taken. Telithromycin is classified as a mechanism-based (or irreversible) CYP3A4 inhibitor — it forms a stable complex with the CYP3A4 enzyme that inactivates it. Unlike competitive inhibitors whose effect disappears as the inhibitor is cleared from plasma, mechanism-based inhibitors maintain their effect for a period after drug clearance because new CYP3A4 enzyme must be synthesized to replace the inactivated enzyme. The residual inhibitory effect of telithromycin persists for approximately 1 to 2 weeks after the last dose as the inactivated enzyme pool turns over and is replaced by newly synthesized functional CYP3A4. During this post-treatment window, cariprazine and DDCAR continue to accumulate at the reduced clearance rate despite the antibiotic being discontinued. Restoring the cariprazine dose immediately after telithromycin is stopped would be pharmacokinetically premature — the patient should be monitored for 1 to 2 additional weeks before dose restoration to allow CYP3A4 activity to return to baseline.

• Option B: Option B is incorrect because mechanism-based CYP3A4 inhibition does not produce permanent enzyme downregulation; the inhibitory effect is time-limited and resolved as new enzyme is synthesized, typically within 1 to 2 weeks; permanent metabolic pathway suppression from short-course telithromycin is not pharmacologically established.
• Option C: Option C is incorrect because while clinical observation periods are important, the specific reason for the timing concern in this case is pharmacokinetic — residual CYP3A4 inhibition from mechanism-based inhibition — not a general guideline requiring a 4-week observation period after any dose reduction.
• Option D: Option D is correct but addresses only the longer-term DDCAR washout management consideration rather than the immediate reason why dose restoration cannot occur on the day telithromycin ends; the DDCAR washout issue is a real consideration, but the more specific and clinically immediate reason for caution is the residual CYP3A4 inhibitory effect from telithromycin's mechanism-based enzyme inactivation persisting for 1 to 2 weeks post-dose.

ANSWER: B

Rationale:

The nurse's concern is pharmacologically well-founded for CYP1A2-metabolized antipsychotics — specifically asenapine, clozapine, and olanzapine — whose plasma levels rise when smoking ceases and CYP1A2 induction is lost. However, the pharmacological basis for this concern does not apply to cariprazine. Tobacco smoke induction of hepatic enzymes is mediated by polycyclic aromatic hydrocarbons acting through the aryl hydrocarbon receptor, which specifically upregulates CYP1A2. This inductive effect is selective for CYP1A2 and related CYP1A enzymes; it does not meaningfully induce CYP3A4. Cariprazine is metabolized by CYP3A4, not by CYP1A2. Consequently, changes in CYP1A2 activity from smoking or smoking cessation have no pharmacokinetic effect on cariprazine metabolism, and no dose adjustment is needed when the patient stops smoking. This is an important discrimination that protects against both under-treatment (unnecessary dose reduction) and over-reaction (implementing dose changes that have no pharmacokinetic basis). The clinical vigilance required after smoking cessation is real but agent-specific: it applies to CYP1A2 substrates, not CYP3A4 substrates.

• Option A: Option A is incorrect because tobacco smoke does not meaningfully induce CYP3A4; the CYP1A2-selective induction by PAHs does not translate to a parallel CYP3A4 inductive effect, and cariprazine levels are not elevated by removal of tobacco-associated CYP3A4 induction.
• Option C: Option C is incorrect because nicotine is not a clinically meaningful CYP3A4 inducer at doses delivered by cigarette smoking; the nicotine delivered by smoking does not produce a measurable induction of CYP3A4 that would be lost upon cessation and require compensatory dose increase.
• Option D: Option D is incorrect because nicotine withdrawal does not produce CYP3A4-inhibitory metabolites; there is no established pharmacological mechanism by which stopping smoking transiently inhibits CYP3A4 in a way that requires a 2-week cariprazine dose reduction.

ANSWER: D

Rationale:

The clinical presentation — a 68 mmHg systolic drop on orthostasis with no prior cardiovascular history, occurring 16 hours after the first dose of iloperidone initiated at full maintenance dose — is the textbook presentation of iloperidone-induced orthostatic hypotension from alpha-1 adrenergic receptor blockade. Iloperidone's potent alpha-1 blockade impairs the peripheral vasoconstriction reflex that maintains blood pressure against gravitational fluid shifts on standing. When initiated at full dose without the approved titration protocol, this pharmacodynamic effect overwhelms cardiovascular compensatory mechanisms before any adaptation can occur, producing symptomatic orthostasis. The QTc of 452 ms is clinically relevant and warrants monitoring, but it does not explain the specific hemodynamic pattern of profound orthostatic hypotension — QTc-related events manifest as arrhythmia, not as isolated orthostatic blood pressure collapse. The immediate correct management is: hold further iloperidone doses, ensure patient safety in the supine position, provide supportive care (IV fluids if indicated), and document the prescribing error. When restarted, iloperidone must begin at 1 mg twice daily with 2 mg per day increments over 7 days as approved.

• Option A: Option A is incorrect because a QTc of 452 ms is elevated and warrants monitoring, but QTc elevation alone does not typically cause acute collapse via arrhythmia without a documented arrhythmic event on ECG; the hemodynamic pattern — profound positional blood pressure drop — points specifically to alpha-1 blockade, not arrhythmia.
• Option B: Option B is incorrect because the severity and pharmacodynamic specificity of a 68 mmHg supine-to-standing pressure drop in the temporal context of iloperidone initiation is not consistent with an anxiety-triggered vasovagal episode; continuing iloperidone at the same dose without correction would reproduce or worsen the event.
• Option C: Option C is incorrect because iloperidone does not produce clinically significant acute dystonia as a mechanism for postural instability; its extrapyramidal burden is relatively low, and acute dystonia produces abnormal muscle contractions, not impaired vascular reflex responses; the hemodynamic data confirms a cardiovascular mechanism.

ANSWER: A

Rationale:

Iloperidone is metabolized by both CYP2D6 and CYP3A4, and its pharmacologically active metabolites P88 and P95 are generated through CYP2D6-mediated oxidation. In a CYP2D6 poor metabolizer, the primary CYP2D6-mediated elimination pathway is absent, causing both the parent drug and the active metabolites to accumulate to higher concentrations than in extensive metabolizers at the same dose. Both the parent drug and P88 and P95 contribute to iloperidone's pharmacological effects — D2 receptor occupancy, alpha-1 blockade, and QTc prolongation — meaning that their accumulation in poor metabolizers increases the risk of dose-dependent adverse effects at standard target doses. The FDA prescribing information for iloperidone recommends reducing the dose by approximately 50% in CYP2D6 poor metabolizers: from the standard target of 12 mg twice daily to approximately 6 mg twice daily. The titration protocol still applies at this adjusted target — the patient still initiates at 1 mg twice daily and increases by 2 mg per day over 7 days, but targets 6 mg twice daily rather than 12 mg twice daily.

• Option B: Option B is incorrect because P88 and P95 are not restricted to causing side effects; they are pharmacologically active metabolites that contribute to both the therapeutic D2 receptor occupancy and the adverse effect profile including QTc prolongation and alpha-1-mediated orthostatic effects; describing them as purely responsible for side effects misrepresents their pharmacology.
• Option C: Option C is incorrect because a 75% dose reduction to 3 mg twice daily is not the prescribing information recommendation for CYP2D6 poor metabolizers; the approved guidance is approximately 50% reduction; a 75% reduction may be excessively conservative and risk inadequate antipsychotic coverage.
• Option D: Option D is incorrect because a 25% dose reduction to 9 mg twice daily underestimates the pharmacokinetic impact of absent CYP2D6 activity on iloperidone and its active metabolites; the prescribing information specifies approximately 50% reduction, not 25%.

ANSWER: B

Rationale:

This question requires integrating two distinct pharmacodynamic concerns for iloperidone — the titration-managed alpha-1 blockade and the separately operating QTc-prolonging hERG channel effect — and applying appropriate clinical judgment to the QTc finding. A 32 ms increase in QTc from a baseline of 438 ms to 470 ms is a clinically meaningful finding. The baseline QTc of 438 ms was already at the upper end of normal, and the 32 ms rise during iloperidone titration is consistent with drug-induced hERG potassium channel blockade producing dose-dependent QTc prolongation. At 470 ms, the QTc has not yet reached the 500 ms level that most guidelines cite as a threshold for mandatory drug discontinuation in the absence of arrhythmia, but the trajectory is concerning: continued dose escalation toward the target of 6 mg twice daily carries the risk of further QTc prolongation above 500 ms. The appropriate response is nuanced: this does not mandate immediate discontinuation, but it does require cardiology consultation, correction of any QTc-prolonging cofactors (electrolyte abnormalities, other QTc-active medications), careful reassessment of the risk-benefit ratio for reaching the target dose, and ongoing ECG monitoring before the titration proceeds. The alpha-1 titration management continues in parallel as a separate safety requirement.

• Option A: Option A is incorrect because a QTc of 470 ms without arrhythmia does not meet the threshold that mandates immediate discontinuation; while it warrants serious attention and reassessment, the clinical guideline threshold for emergency drug discontinuation is typically 500 ms or documentation of torsade de pointes.
• Option C: Option C is incorrect because a 32 ms increase is substantially greater than normal diurnal QTc variation (typically less than 20 ms under standardized conditions) and is not attributable to measurement noise; drug-induced QTc prolongation is the pharmacologically appropriate explanation for this finding in the context of iloperidone initiation.
• Option D: Option D is incorrect because iloperidone's QTc prolongation is mediated by direct hERG potassium channel blockade — a pharmacodynamic mechanism entirely independent of alpha-1 adrenergic effects; the QTc prolongation does not resolve as cardiovascular adaptation to alpha-1 blockade develops; these are two separate pharmacological properties with separate clinical timelines.

ANSWER: C

Rationale:

This case mirrors the pharmacokinetic scenario established in Case 2, Q4 for aripiprazole, now applied to iloperidone. The patient's CYP2D6 poor metabolizer status means that CYP2D6-mediated clearance of iloperidone — including the formation and elimination of active metabolites P88 and P95 — is genetically absent. The current dose of 6 mg twice daily has been calibrated for this baseline by applying the 50% reduction from the standard 12 mg. At 6 mg twice daily, iloperidone clearance is being maintained entirely by the CYP3A4 pathway (and minor routes). When itraconazole is added and strongly inhibits CYP3A4, this last functional primary clearance pathway is also substantially impaired. Both the parent drug and the active metabolites will accumulate further from their already-elevated poor-metabolizer baseline, increasing the risk of dose-dependent adverse effects including QTc prolongation and orthostatic hypotension. The correct management is to reduce iloperidone further from the current 6 mg twice daily — by approximately 50%, to approximately 3 mg twice daily — for the duration of itraconazole therapy, with close monitoring for adverse effects. When itraconazole is discontinued, iloperidone should be returned to the CYP2D6 poor-metabolizer-appropriate dose of 6 mg twice daily.

• Option A: Option A is incorrect because the prior dose reduction for CYP2D6 poor metabolizer status does not provide a "buffer" against subsequent CYP3A4 inhibition; the two adjustments address different metabolic pathway impairments and are not cumulative in the sense that one substitutes for the other; the patient requires an additional reduction when CYP3A4 is inhibited.
• Option B: Option B is incorrect because applying the standard 50% single-pathway inhibitor rule from the current dose (6 mg → 3 mg) addresses the CYP3A4 inhibition appropriately but the explanation is incomplete — the critical clinical insight is that this patient's poor metabolizer status makes the addition of a CYP3A4 inhibitor equivalent to dual-pathway blockade, requiring further dose reduction beyond the CYP2D6 adjustment, not merely a standard single-pathway adjustment from the current dose.
• Option D: Option D is incorrect because iloperidone, unlike lurasidone, retains some residual minor metabolic clearance beyond its two primary CYP pathways; it does not accumulate indefinitely, and the combination is not pharmacologically equivalent to lurasidone plus a CYP3A4 inhibitor; dose reduction is the appropriate management, not discontinuation.

ANSWER: A

Rationale:

The pharmacological explanation for asenapine's mandatory sublingual route is its virtually complete first-pass hepatic extraction after gastrointestinal absorption. When asenapine reaches the intestinal epithelium, it is absorbed into the portal venous system and passes through the liver before entering the systemic circulation. The liver's CYP1A2-mediated and glucuronidation-mediated metabolism extracts essentially all absorbed drug in this first pass, leaving negligible concentrations to enter the systemic circulation. Oral bioavailability by the swallowed route is therefore approximately zero at any clinically practical dose. Sublingual administration places the dissolving tablet in contact with the highly vascularized buccal mucosa, from which drug is absorbed directly into the systemic venous circulation — bypassing the portal circulation and hepatic first-pass extraction entirely. This route achieves approximately 35% bioavailability. A patient who swallows the tablet — or who fails to hold the dissolving tablet under the tongue long enough — will receive essentially no drug systemically, regardless of how well the tablet dissolves in the stomach. This is why patient education must explicitly explain the mechanism, not just the instruction, to reinforce compliance with the sublingual technique.

• Option B: Option B is incorrect because asenapine is not acid-labile; chemical degradation in gastric acid is not the mechanism of poor oral bioavailability; the mechanism is enzymatic first-pass hepatic metabolism, not chemical decomposition before intestinal absorption.
• Option C: Option C is incorrect because while P-glycoprotein does contribute to the poor bioavailability of some drugs, it is not the established primary mechanism of asenapine's near-zero oral bioavailability; the primary mechanism is hepatic first-pass extraction, not intestinal P-glycoprotein efflux.
• Option D: Option D is incorrect because colonic bacterial conjugation is not the mechanism of asenapine's first-pass loss; asenapine's first-pass metabolism occurs in the liver through CYP1A2 and glucuronidation enzymes immediately after intestinal absorption, not through colonic bacterial action.

ANSWER: B

Rationale:

This question applies the tobacco-CYP1A2 induction pharmacokinetic interaction to asenapine in an onset-of-symptoms scenario. Asenapine is metabolized primarily by CYP1A2 and direct glucuronidation. Polycyclic aromatic hydrocarbons (PAHs) in tobacco smoke are potent inducers of CYP1A2 through activation of the aryl hydrocarbon receptor, which drives transcriptional upregulation of CYP1A2 enzyme expression. As CYP1A2 activity increases over the first 1 to 2 weeks of smoking initiation, asenapine is metabolized more rapidly, and plasma levels at the previously therapeutic dose fall progressively below the therapeutic range. The worsening psychiatric symptoms over 3 weeks following smoking initiation, with confirmed medication compliance and technique, are consistent with this pharmacokinetic mechanism. The appropriate clinical response is to increase the asenapine dose to compensate for the smoking-induced CYP1A2 induction. Critically, the patient and clinical team should be counseled that if the patient subsequently stops smoking, the CYP1A2 induction will reverse over 1 to 2 weeks, levels will rise, and the dose increase would then produce toxicity — requiring dose reduction back to the pre-smoking level. This bidirectional CYP1A2 pharmacokinetic vigilance is the core management principle for CYP1A2-metabolized drugs and tobacco use.

• Option A: Option A is incorrect because nicotine-mediated alpha-adrenergic vasoconstriction of buccal mucosa is not an established pharmacokinetic mechanism for reduced asenapine absorption; the mechanism is hepatic CYP1A2 induction by PAHs, not mucosal blood flow reduction by nicotine.
• Option C: Option C is incorrect because smoking does not reduce salivary flow in a way that impairs sublingual dissolution to clinically meaningful degree as a mechanism of reduced asenapine levels; the subtherapeutic plasma level and the temporal relationship to smoking initiation point clearly to CYP1A2 induction, not dissolution problems.
• Option D: Option D is incorrect because the relevant enzyme for the tobacco-asenapine interaction is CYP1A2, not CYP3A4; tobacco smoke does not induce CYP3A4 through the pregnane X receptor or any other established mechanism at clinically relevant smoking levels; describing the interaction as CYP3A4-mediated fundamentally misidentifies the pharmacology.

ANSWER: C

Rationale:

This question completes the bidirectional CYP1A2-asenapine interaction cycle established in Q2. The patient's current asenapine dose was increased to compensate for smoking-induced CYP1A2 activity; this dose is therefore calibrated for elevated CYP1A2-mediated clearance. When smoking ceases, the PAH inductive stimulus is removed and CYP1A2 activity declines progressively toward its uninduced baseline over approximately 1 to 2 weeks. As CYP1A2 activity falls, asenapine clearance decreases — meaning that more drug accumulates at each dose — and plasma levels rise from their smoking-induced suppressed level toward and potentially above the therapeutic range. A patient on a dose calibrated for high CYP1A2 induction who stops smoking without dose adjustment is at risk for developing asenapine toxicity — sedation, extrapyramidal symptoms — as CYP1A2 activity normalizes. The correct management is to anticipate this pharmacokinetic shift: begin monitoring for emerging adverse effects within the first week after smoking cessation, and proactively reduce the asenapine dose toward the pre-smoking baseline, with clinical and potentially plasma-level-guided titration.

• Option A: Option A is incorrect because there is no established pharmacological phenomenon of CYP1A2 activity rebounding above baseline after cessation of chronic induction; CYP1A2 activity returns smoothly to baseline without overshoot; the concern is levels rising due to induction loss, not an upregulation rebound.
• Option B: Option B is incorrect because nicotine replacement therapy — transdermal patches, gum, lozenges — delivers nicotine but does not deliver polycyclic aromatic hydrocarbons; PAHs are the specific CYP1A2 inducers in tobacco smoke, generated by combustion; nicotine itself does not induce CYP1A2; therefore switching from cigarettes to nicotine replacement removes the CYP1A2 inductive stimulus just as effectively as stopping all nicotine use.
• Option D: Option D is incorrect for the same pharmacological reason: nicotine is not the CYP1A2-inducing component of tobacco smoke; PAHs from combustion are the responsible inducers; dose adjustment is needed when combustion-based smoking ceases, regardless of whether nicotine replacement continues.

ANSWER: D

Rationale:

This question requires reasoning through the pharmacokinetic relationship between baseline CYP1A2 activity and the impact of subsequent inhibition. The key insight is that fluvoxamine's CYP1A2 inhibition is superimposed on whatever the current CYP1A2 activity level is. In a smoker, CYP1A2 is highly induced — substantially elevated above the uninduced baseline. Adding fluvoxamine to a smoker inhibits CYP1A2 from this elevated starting point; there is "more CYP1A2 to inhibit," and the residual CYP1A2 activity after inhibition may still be sufficient to provide meaningful clearance. In a non-smoker at uninduced CYP1A2 baseline, adding fluvoxamine inhibits CYP1A2 from the lower baseline level; there is less CYP1A2 activity to begin with, and the same degree of inhibition can reduce residual CYP1A2-mediated clearance to a more clinically critical degree. This means the pharmacokinetic impact of adding fluvoxamine on asenapine levels is potentially greater in a non-smoker than in a smoker, because the absolute reduction in CYP1A2-mediated clearance from the lower baseline is proportionally more significant. The management principle is: asenapine dose reduction is required when fluvoxamine is added, and the clinician should be alert that the level increase may be larger in this non-smoking patient than it would have been when the patient was smoking.

• Option A: Option A is incorrect because the pharmacokinetic effect of CYP1A2 inhibition is not identical across smoking and non-smoking states; the baseline CYP1A2 activity level determines the residual clearance capacity after inhibition, and these differ substantially between induced (smoking) and uninduced (non-smoking) states.
• Option B: Option B is incorrect because it reverses the pharmacokinetic reasoning; inhibiting CYP1A2 from a lower (uninduced) baseline produces a more critical reduction in residual clearance than inhibiting it from the elevated induced state, not a smaller impact; the non-smoking state is actually the more vulnerable pharmacokinetic scenario for CYP1A2 inhibition.
• Option C: Option C is incorrect because while the asenapine dose is indeed lower in a non-smoker, the pharmacokinetic impact is not simply proportional to the starting dose; the critical variable is the residual CYP1A2 activity after inhibition relative to the drug's clearance requirements, and a non-smoker is at greater risk of pharmacokinetically meaningful clearance reduction from CYP1A2 inhibition than a smoker.

ANSWER: B

Rationale:

This selection question requires applying three simultaneous clinical criteria: a specific FDA approval for bipolar I depression, metabolic favorability for a patient with established diabetes and obesity, and cardiac safety at a baseline QTc of 422 ms. Lurasidone satisfies all three. FDA approval: lurasidone is approved for bipolar I depression as monotherapy and adjunctive therapy with lithium or valproate, supported by the PREVAIL 1 and PREVAIL 2 trials demonstrating superiority over placebo on depressive rating scales without significant mood switching risk. Metabolic profile: lurasidone demonstrates average weight gain of approximately 0.7 kg at 6 weeks with minimal glucose and lipid effects — the most directly applicable evidence for this patient's specific comorbidity profile among the full-antagonist SGAs. QTc safety: lurasidone does not produce clinically meaningful QTc prolongation, which is favorable relative to agents with hERG channel activity in a patient with a baseline QTc of 422 ms. The mandatory food co-administration instruction (at least 350 calories per dose) must be incorporated into patient education.

• Option A: Option A is incorrect because ziprasidone does not have FDA approval for bipolar I depression; its approved bipolar indication is for acute manic or mixed episodes only; off-label use for bipolar depression is not the appropriate first choice when an FDA-approved agent fitting the clinical profile is available.
• Option C: Option C is incorrect because while cariprazine has FDA approval for bipolar I depression based on its own clinical trials, the option's stated rationale — that D3 partial agonism specifically addresses anhedonia and that partial agonism produces fewer metabolic effects — is less directly supported by comparative metabolic data for glucose and weight specifically in diabetic/obese patients than lurasidone's profile; additionally, DDCAR's multi-week accumulation kinetics add management complexity that lurasidone avoids.
• Option D: Option D is incorrect because aripiprazole does not have an FDA-approved indication for bipolar I depression as monotherapy for depressive episodes; its approved bipolar indications are for acute mania and maintenance therapy.

ANSWER: C

Rationale:

This question tests a fundamental but commonly misunderstood pharmacokinetic principle: being a CYP3A4 substrate is categorically different from being a CYP3A4 inhibitor. A substrate is a drug that is metabolized by an enzyme — it is acted upon by the enzyme and does not meaningfully reduce the enzyme's activity for other substrates at clinical concentrations. An inhibitor is a drug that reduces CYP3A4 enzyme activity, raising plasma levels of co-administered substrates. Lurasidone is a CYP3A4 substrate — it is metabolized by CYP3A4 — but it does not inhibit CYP3A4. Simvastatin is also a CYP3A4 substrate — it is metabolized by CYP3A4 — but it also does not inhibit CYP3A4. Because neither drug inhibits the enzyme, neither raises the plasma levels of the other. At clinical concentrations, CYP3A4 substrate competition (two drugs competing for the same enzyme binding site simultaneously) is generally not clinically significant because the enzyme operates in first-order kinetics at clinical drug concentrations and has sufficient capacity to metabolize both drugs without meaningful cross-elevation of either's plasma level. The clinically relevant CYP3A4 interactions are those involving inhibitors (ketoconazole, ritonavir, clarithromycin) or inducers (carbamazepine, rifampin) — not simply another substrate.

• Option A: Option A is incorrect because lurasidone is a CYP3A4 substrate, not a CYP3A4 inhibitor; it does not inhibit CYP3A4 and does not raise simvastatin levels; reducing simvastatin dose in response to lurasidone initiation has no pharmacokinetic basis.
• Option B: Option B is incorrect because simvastatin is a CYP3A4 substrate, not a CYP3A4 inhibitor; substrate competition at clinical concentrations does not produce the magnitude of competitive inhibition that would require dose reduction; simvastatin at 40 mg daily does not impair lurasidone clearance through shared substrate status.
• Option D: Option D is incorrect because neither lurasidone nor simvastatin undergoes mechanism-based CYP3A4 inactivation; neither drug is a CYP3A4 inhibitor of any type, and metformin is not metabolized by CYP3A4 — it is renally cleared and not a CYP substrate.

ANSWER: D

Rationale:

Lurasidone's FDA-approved bipolar indications are specifically for the treatment of major depressive episodes associated with bipolar I disorder — as monotherapy and as adjunctive therapy with lithium or valproate. It does not have approval for the treatment of acute manic or mixed episodes of bipolar I disorder. This is clinically important because the two phases of bipolar disorder require different pharmacological management, and FDA approvals for bipolar agents are often phase-specific. When this patient develops an acute manic episode, lurasidone's existing depression coverage does not extend to antimanic efficacy from a regulatory or evidence standpoint for this indication. The appropriate management is to add an agent with demonstrated and approved antimanic activity — lithium, valproate, or a second-generation antipsychotic with a manic episode approval such as olanzapine, quetiapine, risperidone, aripiprazole, or ziprasidone (among others). Lurasidone may be continued during the manic episode for its depressive phase protection, particularly relevant in bipolar I patients where rapid cycling is a concern, but it should not be relied upon as the primary antimanic treatment.

• Option A: Option A is incorrect because lurasidone does not have FDA approval for bipolar I mania as monotherapy; its approved bipolar indication is bipolar I depression only; the claim that higher-dose lurasidone achieves antimanic activity through increased D2 occupancy is not supported by the approved indication or clinical trial evidence for the manic phase.
• Option B: Option B is incorrect because while many SGAs do have antimanic activity through D2 blockade, this does not translate to a regulatory or evidence-based class effect justification for off-label antimanic use of lurasidone when approved agents are available; additionally, lurasidone's partial or full antagonist status and its specific clinical trial evidence are the appropriate bases for indication selection, not presumed class effects.
• Option C: Option C is incorrect because lurasidone does not have FDA approval for bipolar I mania even as adjunctive therapy with lithium; the adjunctive approval with lithium or valproate is specifically for the bipolar I depressive phase, not for the manic phase; stating it has adjunctive manic approval misrepresents the prescribing information.

ANSWER: A

Rationale:

This question applies the substrate-versus-inhibitor pharmacokinetic distinction — established conceptually in Q2 — to the specific combination of lurasidone and aripiprazole. Lurasidone is a CYP3A4 substrate (metabolized by CYP3A4) but does not inhibit CYP3A4 or any other clinically significant CYP enzyme; it has no meaningful inhibitory activity at CYP2D6, CYP3A4, or other major drug-metabolizing enzymes. Aripiprazole is a CYP2D6 and CYP3A4 substrate but does not inhibit these enzymes either. Because neither drug inhibits the other's primary metabolic enzymes, there is no pharmacokinetic interaction between them from a CYP substrate competition standpoint at clinical concentrations. Both can be co-administered without CYP-based dose adjustments for each other. The relevant pharmacokinetic interactions for lurasidone are with inhibitors and inducers of CYP3A4 (ketoconazole, ritonavir, carbamazepine, rifampin, etc.), not with other CYP3A4 substrates. The relevant interactions for aripiprazole are with inhibitors and inducers of CYP2D6 and CYP3A4 (fluoxetine, paroxetine, ketoconazole, carbamazepine, etc.), not with lurasidone. The absence of a clinically significant drug-drug interaction between these two agents is the correct answer.

• Option B: Option B is incorrect because lurasidone is not a CYP2D6 inhibitor; it is a CYP3A4 substrate without established inhibitory activity at CYP2D6; reducing aripiprazole on the basis of lurasidone-induced CYP2D6 inhibition has no pharmacokinetic basis.
• Option C: Option C is incorrect because aripiprazole is a CYP3A4 substrate, not a CYP3A4 inhibitor; it does not inhibit CYP3A4 and does not raise lurasidone plasma levels; the combination is not a relative contraindication on pharmacokinetic grounds.
• Option D: Option D is incorrect because the concept of "mutual competitive substrate inhibition" producing clinically significant bidirectional level elevation is not applicable to these two drugs at therapeutic concentrations; CYP3A4 substrate competition is not a clinically recognized mechanism for meaningful pharmacokinetic interactions between co-administered substrates at standard doses.

ANSWER: C

Rationale:

Aripiprazole is metabolized by both CYP2D6 and CYP3A4. Fluoxetine is a strong CYP2D6 inhibitor but not a meaningful CYP3A4 inhibitor. When only CYP2D6 is inhibited, aripiprazole retains its CYP3A4-mediated clearance pathway, which partially compensates for the lost CYP2D6 contribution. The net result is an approximately two-fold increase in aripiprazole plasma levels — a manageable interaction that is corrected by a 50% dose reduction: 15 mg × 50% = 7.5 mg daily. This dose is maintained for the duration of fluoxetine co-administration and restored to 15 mg if fluoxetine is discontinued.

• Option A: Option A is incorrect because fluoxetine's serotonergic mechanism does not pharmacodynamically antagonize aripiprazole's D2 partial agonist activity through receptor competition; 5-HT reuptake inhibition and D2 partial agonism operate through entirely separate receptor systems without direct pharmacodynamic antagonism; the interaction is pharmacokinetic, and the appropriate response is dose reduction, not increase.
• Option B: Option B is incorrect because CYP3A4 is not upregulated compensatorily when CYP2D6 is inhibited; the compensatory clearance through CYP3A4 is a passive pharmacokinetic consequence of the remaining enzyme activity, not an active upregulation; because CYP3A4 cannot fully replace CYP2D6-mediated clearance, plasma levels do rise approximately two-fold and dose reduction is required.
• Option D: Option D is incorrect because the simultaneous inhibition of aripiprazole and its metabolite through CYP2D6 does not constitute dual-pathway inhibition in the sense that triggers the 75% dose reduction rule; the 75% rule applies to inhibition of two separate enzyme pathways (CYP2D6 and CYP3A4), not to inhibition of one enzyme that metabolizes both the parent drug and its metabolite.

ANSWER: D

Rationale:

When both CYP2D6 and CYP3A4 are simultaneously strongly inhibited, aripiprazole loses both primary clearance pathways. The pharmacokinetic consequence is an approximately four-fold increase in aripiprazole exposure relative to the uninhibited baseline. The prescribing information recommends reducing aripiprazole to approximately 25% of the original dose — a 75% total reduction from the pre-inhibitor baseline of 15 mg — when both pathways are simultaneously strongly inhibited: 15 mg × 25% = 3.75 mg. Note that the target is 25% of the original (uninhibited) dose, not 25% of the current fluoxetine-adjusted dose; this is because the dose reduction is calculated relative to the baseline exposure that both inhibitors together are elevating, and the appropriate correction is to the original pre-inhibitor level.

• Option A: Option A is incorrect because maintaining the aripiprazole at 7.5 mg — a 50% reduction from baseline — is appropriate when only one pathway is inhibited; with both pathways now inhibited, the residual clearance that the 7.5 mg dose depended on (CYP3A4) has been eliminated by ketoconazole; the patient at 7.5 mg with both pathways inhibited will have plasma levels approximately double the target, requiring further reduction.
• Option B: Option B is incorrect because ketoconazole at doses used for oral candidiasis is a potent CYP3A4 inhibitor — not a partial inhibitor — and a reduction to only 5 mg from 7.5 mg does not achieve the pharmacokinetically appropriate 25% of original dose target.
• Option C: Option C is incorrect because dual CYP pathway inhibition does not constitute an absolute contraindication for aripiprazole; unlike lurasidone's exclusive single-enzyme dependence, aripiprazole retains residual minor clearance mechanisms and the interaction is well-established as pharmacokinetically manageable with dose reduction to 25% of the original dose.

ANSWER: A

Rationale:

This question requires tracking the pharmacokinetic state of aripiprazole as inhibitors are added and removed sequentially. With ketoconazole discontinued, CYP3A4-mediated clearance of aripiprazole is restored. Fluoxetine continues to inhibit CYP2D6, so aripiprazole now has one functional primary clearance pathway (CYP3A4) and one inhibited pathway (CYP2D6) — the same pharmacokinetic situation as when fluoxetine was first added in Q1. The single-pathway CYP2D6 inhibition rule applies: aripiprazole should be at 50% of the original baseline dose, which is 15 mg × 50% = 7.5 mg. The dose is therefore increased from the dual-inhibition dose of 3.75 mg back to the single-inhibition dose of 7.5 mg once ketoconazole is cleared. This transition should occur promptly as ketoconazole is discontinued, since the CYP3A4 restoration begins as the competitive inhibitor is cleared from plasma.

• Option B: Option B is incorrect because CYP2D6 inhibition by fluoxetine is not pharmacokinetically negligible when CYP3A4 is functioning normally; CYP2D6 provides a meaningful contribution to aripiprazole clearance, and its inhibition produces an approximately two-fold level increase that requires the 50% dose reduction; returning to the full 15 mg dose while CYP2D6 remains inhibited would produce supratherapeutic aripiprazole levels.
• Option C: Option C is incorrect in the context of a competitive reversible inhibitor: ketoconazole is primarily a competitive inhibitor (not exclusively mechanism-based), and its inhibitory effect dissipates as the drug is cleared from plasma within days of the last dose; while telithromycin does form mechanism-based complexes requiring 1 to 2 weeks to reverse, ketoconazole's inhibition resolves much more promptly with drug clearance.
• Option D: Option D is incorrect because CYP3A4 does not undergo reactive upregulation or overshoot after competitive inhibitor removal; CYP3A4 simply returns to its baseline uninduced activity as the inhibitor is cleared; there is no transient CYP3A4 activity surge requiring dose reduction.

ANSWER: B

Rationale:

This final question requires tracking two simultaneous pharmacokinetic changes and determining the net dose requirement. Two events happen concurrently: fluoxetine is discontinued (removing CYP2D6 inhibition, restoring CYP2D6-mediated clearance toward baseline) and carbamazepine is started (inducing CYP3A4, substantially accelerating CYP3A4-mediated clearance above baseline). The pharmacokinetic net effect is not neutral. When fluoxetine is removed, aripiprazole clearance returns to the uninhibited level — where 15 mg was the appropriate dose. Carbamazepine then applies its CYP3A4 induction to this restored uninhibited system: the FDA-recommended management is to double the aripiprazole dose when a strong CYP3A4 inducer is added to a patient with normal (uninhibited) CYP pathways: 15 mg × 2 = 30 mg. The correct dose after both changes are accounted for is 30 mg. The transition should proceed in a pharmacokinetically logical sequence: as fluoxetine clears over days to weeks, CYP2D6 inhibition resolves and aripiprazole clearance returns toward baseline; as carbamazepine builds to steady state and full induction over 2 to 4 weeks, CYP3A4 activity increases. The dose increase to 30 mg should be implemented as carbamazepine reaches steady state and the full inductive effect is established.

• Option A: Option A is incorrect because carbamazepine's CYP3A4 induction is not offset by the restoration of CYP2D6 activity; the two changes operate on different enzymes; CYP2D6 restoration brings clearance back to the uninhibited baseline, while CYP3A4 induction accelerates clearance above that baseline; returning to only 15 mg would leave the patient on a sub-induction dose.
• Option C: Option C is incorrect because the 22.5 mg suggestion is based on an arithmetic averaging of the two pharmacokinetic changes that does not reflect how CYP induction and inhibition reversal work in practice; the correct approach is to identify the uninhibited baseline (15 mg) and then apply the induction-direction dose-doubling rule to arrive at 30 mg.
• Option D: Option D is incorrect because the simultaneous removal of CYP2D6 inhibition and addition of CYP3A4 induction do not produce approximately canceling pharmacokinetic effects; CYP2D6 restoration brings the system to baseline while CYP3A4 induction drives clearance above baseline — the net effect is accelerated clearance relative to the uninhibited state, requiring dose escalation above 15 mg.